Alchemab

News

Alchemab's chief executive, Jane Osbourn

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

R&D

Turning drug development on its head

In episode 98 of the pharmaphorum podcast , host Jonah Comstock and Alchemab CEO Young Kwon discuss innovative new routes to drug discovery

News

Breast cancer assayed with anti HER-2 antibody

EU starts review of first-line Enhertu for breast cancer

EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks